Compass Therapeutics
Compass Therapeutics' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$49 million. The diluted share count rose 14.8%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Compass Therapeutics does
Compass Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-based cancer drugs. Clinical-stage means its drug candidates are still being tested in people and none is approved for sale. It focuses on how blood vessel growth, the immune system and tumor growth relate to each other.
It has four clinical product candidates. The lead one, tovecimig (CTX-009), is a bispecific antibody (one that binds two targets) aimed at DLL4 and VEGF-A. It is being tested with the chemotherapy drug paclitaxel in a Phase 2/3 trial in patients with biliary tract cancer who had one earlier treatment. The company says the trial met its main goal, with an overall response rate of 17.1% for tovecimig plus paclitaxel against 5.3% for paclitaxel alone. The other three are CTX-471, CTX-8371 and CTX-10726.
The company has no products approved for sale and has never earned revenue from product sales. It plans to test its candidates alone and in combination, and says it needs more financing to keep going.
Its biggest risks, as it describes them
- It has no approved products, a history of significant losses, and may never be profitable.
- It will need substantial additional financing, which may not be available on acceptable terms.
- Clinical trials are lengthy and costly, and their results are uncertain.
- Early or interim results may not predict later trial results.
- Its antibody drugs are a new class of therapy, making time and cost hard to predict.
Income statement
Compass Therapeutics lost money in fiscal 2025: a net loss of $66 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 144 | 187 | 152 | 127 | 209 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −144 | −187 | −152 | −127 | −209 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −221.3x | — | — | — | — |
| Current ratio | 13.8x | 12.1x | 19.7x | 15.0x | 15.0x |
| Quick ratio | 13.8x | 12.1x | 19.7x | 15.0x | 15.0x |
Cash flow
Projections
Project Compass Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Compass Therapeutics says to expect
- Cash runway
Based on current operating plans, the anticipated cash runway is into 2028.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $8,750 of Compass Therapeutics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Neil LernerChief Accounting Officer | Bought | 10,000 | $0.59 | $5,900 | Form 4 |
| Sep 24, 2026 | Neil LernerChief Accounting Officer | Bought | 2,500 | $1.14 | $2,850 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 2 of 8 | 2 of 8 |
| Rule of 40 | — | — | — |
| Altman Z'' | 16.11 | 3.28 | 6.28 |
| Accruals ratio | −1.1% | −3.0% | −9.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Pass | Fail |
| F-score | — | 2 of 8 | 2 of 8 |
Compare
Put Compass Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Compass Therapeutics | FY25 | −100.0% | — | — | — | — | 2 | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
8 years of figures
| Fiscal year | FY19 | FY20 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | 0 | 1 | 0 |
| Revenue growth | — | — | — | — | — | — | — | −100.0% |
| Gross profit | — | — | — | — | — | — | — | — |
| Research and development | — | 15 | 15 | 20 | 30 | 38 | 42 | 56 |
| Operating income | −0 | −28 | −28 | −82 | −42 | −50 | −57 | −73 |
| Net income | −0 | −30 | −30 | −82 | −39 | −42 | −49 | −66 |
| Diluted EPS (US$) | −0.01 | −0.96 | −0.96 | −1.31 | — | — | — | — |
| Diluted shares (millions) | 5 | 31 | 31 | 63 | 105 | 127 | 137 | 158 |
| Cash flow | ||||||||
| Cash from operations | −0 | −27 | −27 | −20 | −34 | −41 | −45 | −49 |
| Capital expenditure | — | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Free cash flow | — | −27 | −27 | −21 | −34 | −41 | −45 | −49 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 4 | 4 | 4 | 5 | 6 | 9 | 8 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 0 | 47 | 47 | 144 | 187 | 152 | 127 | 209 |
| Debt incl. finance leases | — | 9 | 9 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 0 | 52 | 52 | 154 | 200 | 157 | 140 | 220 |
| Total liabilities | 0 | 12 | 12 | 14 | 18 | 8 | 15 | 23 |
| Shareholders' equity | −0 | 40 | 40 | 140 | 182 | 148 | 125 | 197 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −6,661.8% | — |
| Net margin | — | — | — | — | — | — | −5,808.8% | — |
| Free cash flow margin | — | — | — | — | — | — | −5,282.2% | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | −148.0% | −148.0% | −91.3% | −24.4% | −25.7% | −36.1% | −41.3% |
| Return on assets | — | −113.7% | −113.7% | −79.9% | −22.2% | −23.8% | −33.2% | −36.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |